<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4781">
  <stage>Registered</stage>
  <submitdate>13/01/2015</submitdate>
  <approvaldate>13/01/2015</approvaldate>
  <nctid>NCT02340234</nctid>
  <trial_identification>
    <studytitle>A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis</studytitle>
    <scientifictitle>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-000049-56</secondaryid>
    <secondaryid>GS29250</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lebrikizumab
Treatment: drugs - Placebo
Treatment: drugs - TCS Cream

Experimental: Lebrikizumab 250 mg Single Dose + TCS Cream - Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

Experimental: Lebrikizumab 125 mg Single Dose + TCS Cream - Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

Experimental: Lebrikizumab 125 mg Q4W + TCS Cream - Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.

Placebo Comparator: Placebo Q4W + TCS Cream - Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.


Treatment: drugs: Lebrikizumab
Lebrikizumab will be administered SC as per the schedule specified in the respective arms.

Treatment: drugs: Placebo
Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.

Treatment: drugs: TCS Cream
TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants Achieving a 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-50) at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in EASI Score at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From Baseline in EASI Score at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score (EASI-75) at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With a Greater Than or Equal to (&gt;/=) 2 Point Reduction From Baseline in IGA at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From Baseline in IGA at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving an Investigator Global Signs Assessment (IGSA) Score of 0 or 1 at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with a &gt;/=2 Point Reduction From Baseline in IGSA at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From Baseline in IGSA at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From baseline in Severity Scoring of Atopic Dermatitis (SCORAD) at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From baseline in SCORAD at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With a 50% or 75% Reduction From Baseline in SCORAD-50/75 at Week 12</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16</outcome>
      <timepoint>Weeks 12, 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16 and 20</outcome>
      <timepoint>Weeks 12, 16, 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16</outcome>
      <timepoint>Weeks 12, 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16 and 20</outcome>
      <timepoint>Weeks 12, 16, 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16</outcome>
      <timepoint>Weeks 12, 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16 and 20</outcome>
      <timepoint>Weeks 12, 16, 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16</outcome>
      <timepoint>Weeks 12, 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16 and 20</outcome>
      <timepoint>Weeks 12, 16, 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Total % Body Surface Area (BSA) Affected At Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From Baseline in Pruritus as Measured by the Pruritus Visual Analog Scale (VAS) at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Pruritus as Measured by the Pruritus VAS at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Use (Grams) of TCS From Baseline to Week 12</outcome>
      <timepoint>From Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Use (Grams) of TCS From Week 12 to End of Study or Early Termination</outcome>
      <timepoint>From Week 12 to end of study or early termination (up to approximately 20 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Disease Flares From Baseline to Week 12</outcome>
      <timepoint>From Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in AD Symptoms From Baseline to Week 12, as Assessed by the Atopic Dermatitis Symptom Diary (ADSD)</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in AD-Specific HealthRelated Quality of Life (QoL) From Baseline to Week 12, as Assessed by the Atopic Dermatitis Impact Questionnaire (ADIQ)</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Health-Related QoL From Baseline to Week 12, as Measured by the Dermatology Life Quality Index (DLQI)</outcome>
      <timepoint>Baseline, Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Treatment-Emergent Adverse Events (AEs)</outcome>
      <timepoint>From start of run-in period (Day -14) until study completion (up to approximately 20 Weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Lebrikizumab</outcome>
      <timepoint>Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With ATA to Phospholipase B-Like 2 (PLBL2) Protein</outcome>
      <timepoint>Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Disease Rebound</outcome>
      <timepoint>From Week 12 up to approximately 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Serum Concentration (Cmax) of Lebrikizumab</outcome>
      <timepoint>After first dose of lebrikizumab at Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Reach Cmax (Tmax) of Lebrikizumab</outcome>
      <timepoint>After first dose of lebrikizumab at Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum Serum Concentration (Cmin) of Lebrikizumab</outcome>
      <timepoint>Pre-dose at Weeks 4, 8, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Elimination Half-Life (t1/2) of Lebrikizumab</outcome>
      <timepoint>Pre-dose on Days 1, 8, 29, 43, 57, 85, 113, 141, study discontinuation visit (up to Day 141)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  AD diagnosed by the Hanifin/Rajka criteria and that has been present for at least 1
             year at screening

          -  Moderate to severe AD as graded by the Rajka/Langeland criteria at screening

          -  History of inadequate response to a &gt;/= 1 month (within the 3 months prior to the
             screening visit) treatment regimen of at least daily TCS and regular emollient for
             treatment of AD

          -  EASI score &gt;/= 14 at screening and end of the run-in period

          -  IGA score &gt;/= 3 (5-point scale) at screening and end of the run-in period

          -  AD involvement of &gt;/= 10% BSA at screening

          -  Pruritus VAS score &gt;/= 3 at screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy,
             including lebrikizumab

          -  Use of an investigational agent within 4 weeks prior to screening or within 5
             half-lives of the investigational agent, whichever is longer

          -  History of a severe allergic reaction or anaphylactic reaction to a biologic agent or
             known hypersensitivity to any component of the lebrikizumab injection

          -  Use of any complementary, alternative, or homeopathic medicines including, but not
             limited to, phytotherapies, traditional or non-traditional herbal medications,
             essential fatty acids, or acupuncture within 7 days prior to the run-in period or need
             for such medications during the study

          -  Evidence of other skin conditions; including, but not limited to, T-cell lymphoma or
             allergic contact dermatitis

          -  Evidence of, or ongoing treatment (including topical antibiotics) for active skin
             infection at screening

          -  Other recent infections meeting protocol criteria

          -  Active tuberculosis requiring treatment within the 12 months prior to Visit 1

          -  Evidence of acute or chronic hepatitis or known liver cirrhosis

          -  Known immunodeficiency, including human immunodeficiency virus (HIV) infection

          -  Use of a topical calcineurin inhibitor (TCI) at the time of screening, unless the
             participant is willing to stop TCI use during the study (including the run-in period)
             and, in the investigator's opinion, it is safe to do so

          -  Clinically significant abnormality on screening electrocardiogram (ECG) or laboratory
             tests that, in the opinion of the investigator, may pose an additional risk in
             administering study drug or TCS to the participant

          -  Known current malignancy or current evaluation for a potential malignancy, including
             basal or squamous cell carcinoma of the skin or carcinoma in situ

          -  History of malignancy within 5 years prior to screening, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine
             cancer</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>212</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>St George Dermatology and Skin Cancer Centre - Kogarah</hospital>
    <hospital>Skin &amp; Cancer Foundation - Carlton</hospital>
    <hospital>Royal Melbourne Hospital; Dermatology Department - Parkville</hospital>
    <hospital>Fremantle Dermatology - Fremantle</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Usti nad Labem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Tarnow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Navarra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>ZÃ¼rich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dudley</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Poole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy
      of lebrikizumab administered subcutaneously (SC) in adult participants with persistent
      moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical
      corticosteroids (TCS). The study includes a screening visit, a 2-week run-in period, a
      12-week blinded treatment period, and an 8-week safety follow-up period. Following screening
      visit, eligible participants will enter in run-in period (Days - 14 to - 1) during which a
      protocol-specified topical therapy regimen will be initiated. At the end of the run-in
      period, participants who have: 1) demonstrated compliance with the protocol-specified TCS
      regimen, and 2) who continue to fulfill the eligibility criteria will be randomized.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02340234</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>